text:
Due to rising numbers of COVID-19 infections in our community, NHO strongly encourages the use of medical-grade masks for patients and visitors. If you do not have a medical-grade mask (3-ply surgical or procedure mask) we will be happy to provide one for you at the clinic. See any NHO team member for assistance. Thank you for helping us keep each other safe!
Blastic Phase
Chronic myeloid leukemia (CML) is the abnormal growth of relatively mature myeloid (white blood) cells. Half of all patients with CML are diagnosed after the age of 67.
CML is associated with a chromosomal abnormality in which genetic material from chromosome 9 is transferred to chromosome 22. The chromosome containing the genetic switch is called the Philadelphia chromosome; this chromosome plays a role in the development of CML.
The exchange of genetic information that produces the Philadelphia chromosome brings together two genes: the BCR (breakpoint cluster region) gene on chromosome 22 and the ABL (Ableson leukemia virus) gene on chromosome 9. The combination of these two genes into the single BCR-ABL gene results in the production of a protein that contributes to uncontrolled cell growth.
Initially in CML, there is a gradual increase in mature, abnormal myeloid cells in the bone marrow. These cells eventually spill into the blood and other organs, causing symptoms such as fatigue from anemia or an enlarged spleen. The increase in leukemic cell numbers occurs slowly at first and is referred to as the chronic phase, but these cells invariably begin to increase more rapidly and/or include less mature cells, resulting in the accelerated or blastic phase. In order to understand the best treatment options available for chronic myeloid leukemia, it is important to know the phase of leukemia, since all new treatment information concerning chronic myeloid leukemia is categorized and discussed by the phase of disease.
Measuring Response to Treatment
Initial response to therapy is indicated by normalization of the peripheral blood counts (white blood cells, platelets and red blood cells) and return of increased bone marrow cellularity to normal. Most patients are followed with peripheral blood tests rather than repeated bone marrow examination. Cells collected from the bone marrow or peripheral blood will contain the Philadelphia chromosome, and cytogenetic tests (tests that detect chromosomal abnormalities) are used to monitor response to therapy. Currently the majority of newly diagnosed patients with CML will achieve a complete cytogenetic remission (no evidence of Philadelphia chromosome-positive cells). More importantly, in patients with a complete cytogenetic remission a test called polymerase chain reaction (PCR) can determine the completeness of a "molecular" remission by measuring the presence of the BCR-ABL gene. As a general rule, the greater the degree of molecular response the longer the survival of an individual patient.
Staging of Chronic Myeloid Leukemia
Chronic Phase: Patients in the chronic phase of CML have stable disease with only minor symptoms, no cancer outside the bone marrow or spleen and white blood cell and platelet blood counts that are usually greater than normal.
Chronic myeloid leukemia is the abnormal growth of relatively mature myeloid white blood cells. The disease is associated with a chromosomal abnormality (Philadelphia chromosome), where genetic material from chromosome 9 is transferred to chromosome 22. This forms the Philadelphia chromosome, which plays a role in the development of the disease. Chronic myeloid leukemia normally progresses from the chronic phase to an accelerated phase and ultimately, into a blastic or acute leukemia phase over a period of several years.
The diagnosis of blastic phase requires at least one of the following:
Persistent presence of greater than 30% myeloblasts in marrow or peripheral blood
Major increase of white blood cell count to over 50,000
Platelet counts that are increased or decreased
Red blood cell levels that are low despite treatment
Progressive enlargement of the spleen
Tumor nodules outside the bone marrow or spleen
Any abnormal chromosome in addition to the Philadelphia chromosome
Persistent unexplained fever or bone pain.
The diagnosis of the blastic phase requires greater than 30% myeloblasts in marrow or blood. Patients in blastic phase live an average of 3-6 months.
A variety of factors ultimately influence a patient's decision to receive treatment of cancer. The purpose of receiving cancer treatment may be to improve symptoms through local control of the cancer, increase a patient's chance of cure, or prolong a patient's survival. The potential benefits of receiving cancer treatment must be carefully balanced with the potential risks of receiving cancer treatment.
The following is a general overview of the treatment of chronic myeloid leukemia for patients who have progressed to the blastic phase. Circumstances unique to your situation and prognostic factors of your cancer may ultimately influence how these general treatment principles are applied. The information on this Web site is intended to help educate you about your treatment options and to facilitate a mutual or shared decision-making process with your treating cancer physician.
Most new treatments are developed in clinical trials. Clinical trials are studies that evaluate the effectiveness of new drugs or treatment strategies. The development of more effective cancer treatments requires that new and innovative therapies be evaluated with cancer patients. Participation in a clinical trial may offer access to better treatments and advance the existing knowledge about treatment of this cancer. Clinical trials are available for most stages of cancer. Patients who are interested in participating in a clinical trial should discuss the risks and benefits of clinical trials with their physician. To ensure that you are receiving the optimal treatment of your cancer, it is important to stay informed and follow the cancer news in order to learn about new treatments and the results of clinical trials.
When CML progress to the blastic phase, the leukemia cells may look like either myeloid or lymphoid cells and generally respond poorly to treatment. Historically, intensive chemotherapy regimens were used for the treatment of chronic myeloid leukemia, including high-dose cytarabine and daunorubicin. They can induce remissions in 25-35% of patients in blast phase. Patients with a lymphoid blast phase who were treated with therapy similar to that given for acute lymphoid leukemia (Oncovin® (vincristine), Adriamycin® (doxorubicin), Cytoxan® (cyclophosphamide) and dexamethasone) had a complete remission rate of 60%. However, all remissions achieved with chemotherapy in blast phase were of relatively short duration. In 2001, Gleevec® (imatinib) was approved for the treatment of CML in blast crisis.
Treatment of Blastic Phase CML with Gleevec
Most of the patients currently entering blast crisis will have received prior therapy with Gleevec. For those who have not previously been treated with Gleevec, however, Gleevec is a common initial treatment. Many such patients will be treated with Gleevec in preparation for an allogeneic stem cell transplant.
A large, multi-center, phase II trial designed to evaluate Gleevec for the treatment of CML in myeloid blast crisis has been reported.1 Patients were treated with Gleevec in daily oral doses of 400 mg or 600 mg. Eight percent of patients experienced a complete hematologic response, seven percent experienced a complete cytogenetic response, and half the patients survived for longer than seven months. Drug-related adverse events led to discontinuation of therapy in 5% of patients, most often because of low blood cell counts, skin disorders, or gastrointestinal reactions. The researchers concluded that these results demonstrate that Gleevec has substantial activity and a favorable safety profile when used as a single agent in patients with CML in BC.
Researchers affiliated with the STI571 Study (IRIS) Group have reported the results of four years of follow-up of over 1,000 patients with CML with advanced disease. 2 Patients were treated with Gleevec® initially at a dose of 400 mg, but escalating to 600 or 800 mg per day. Few patients in blastic phase survived, suggesting that treatment with an allogeneic stem cell transplant should be considered in those who have a response to Gleevec.
Treatment of Blastic Phase CML with Sprycel
Sprycel® (dasatinib) is a tyrosine kinase inhibitor that appears to have much greater activity against Bcr-Abl than Gleevec. It has been approved by the U.S. FDA for the treatment of patients with CML who are resistant to or intolerant of Gleevec. The FDA cited four single-arm studies involving over 400 patients who were no longer responsive to Gleevec.
One study of Sprycel reported hematological responses in 31 of 44 patients with more advanced CML or ALL. Major cytogenetic responses were observed 35% of patients with more advanced disease.3 However, most patients with ALL or blastic phase CML had relapsed at the time of this report. The main side effect appeared to be low blood cell counts.
Treatment of Blastic Phase CML with Nilotinib
Nilotinib (AMN107) is another drug that targets the Bcr-Abl protein. Nilotinib has a higher activity than Gleevec.. This agent has not yet been approved by the FDA for use in CML but this will likely occur in the very near future.
Recent studies indicate that some patients with CML in blast crisis will respond to nilotinib, including patients who have previously been treated with Gleevec.45 Frequently seen side effects were different from those seen with Gleevec and included rash, liver damage and low blood cell counts.
Allogeneic Stem Cell Transplantation
Prior to the advent of Gleevec and other tyrosine kinase inhibitors, selected patients in blastic phase treated with high-dose chemotherapy and allogeneic stem cell transplant using stem cells from a related donor had a 5-year survival of approximately 15%. There has been significant recent progress in the selection of compatible unrelated stem cell donors and in the development of umbilical cord blood transplants giving most patients an opportunity for a stem cell transplant for CML. There has also been significant progress in the development of reduced-intensity transplant regimens allowing older patients to be transplanted. For more information go to Allogeneic Stem Cell Transplant.
Strategies to Improve Treatment
While significant progress has been made in the treatment of CML, many patients still succumb to leukemia and better treatment strategies are still needed. Future progress in the treatment of leukemia will result from continued participation in appropriate clinical studies. Currently, there are several areas of active exploration aimed at improving the treatment of leukemia.
Allogeneic Stem Cell Transplant: Strategies designed to reduce the toxicity and improve the outcome of Allogeneic Stem Cell Transplant are an active area of study.
Phase I-II Chemotherapy Trials: New chemotherapy drugs continue to be developed and evaluated in phase I-II trials for patients with recurrent cancers. The purpose of phase I trials is to evaluate new drugs in order to determine the best way of administering the drug and whether the drug has any anti-cancer activity in patients. Phase II trials further evaluate new therapies that appear to have promising anti-leukemia activity.
Researchers from MD Anderson Cancer have reported that the chemotherapy drug, homoharringtonine, has significant activity in patients with CML who have failed Gleevec.6
Immunotherapy: Immunotherapy agents have been evaluated in the treatment of patients with minimal residual disease. Results from a phase II trial indicate that the investigative immunotherapy agent GVAX provides promising and durable responses, including long-term molecular remissions, among patients with CML with residual disease while on therapy with Gleevec.7 Unfortunately, the pharmaceutical company sponsoring this study has cancelled plans for further testing of this agent.
Fortunately, other researchers are also developing vaccines for the treatment of CML. Researchers at the Memorial Sloan-Kettering Cancer Center developed and are testing a vaccine which has proven safe and effective in developing an immune responses in patients with CML.8 Researchers from the MD Anderson Cancer Center have reported that patients who have an immune response to the vaccine have improved progression-free survival.9 Researchers from Italy have also developed a vaccine which has been tested in a small number of patients being treated with Gleevec or interferon.10 These researchers suggested that the vaccine produced further reductions in residual molecular disease. Finally, researchers from England have tested a vaccine in patients with CML in the chronic phase; the vaccine appears to improve control of CML in patients responding to Gleevec.11
These vaccine studies are important as they offer an alternative approach to the eradication of minimal residual disease in patients with CML responding to Gleevec or other agents. Vaccines can theoretically kill clones of cells that are drug resistant. Another advantage of vaccines is that they are relatively non-toxic with few side effects.
Development of New Kinase Inhibitors: There are now two agents for treating Gleevec failures: Sprycel and nilotinib. Researchers are continuing to develop new kinase inhibitors with greater activity than those used currently.
Supportive Care: Supportive care refers to treatments designed to prevent and control the side effects of cancer and its treatment. Side effects not only cause patients discomfort, but also may prevent the optimal delivery of therapy at its planned dose and schedule. In order to achieve optimal outcomes from treatment and improve quality of life, it is imperative that side effects resulting from cancer and its treatment are appropriately managed. Side effects of the tyrosine kinase inhibitors; Gleevec, Sprycel and nilotinib are predominantly low white blood cell counts and anemia. Neupogen® (filgrastim) and Neulasta® (pegfilgrastim) can be used to prevent or treat low white blood cell counts12 and Procrit® (epoetin alfa) or Aranesp® (darbepoetin alfa) can be used to prevent or correct anemia.1314For more information, go to Managing Side Effects.
1 Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002:99:3530-3539.
2 Silver, RT, Talpaz M, Sawyers CL, et al. Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials. Proceedings of the American Society of Hematology. Blood. 2004;104:11a, abstract number 23.
3 Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. New England Journal of Medicine. 2006;354:2531-2541.
4 Ottmann O, Kantarjian H, Larson R, et al. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL). Blood 2006;108,528a, abstract 1862.
5 Giles F, Ottmann O, Bhalla K, et al. Update on AMN107 in Leukemia. Proceedings from the 23rd annual Chemotherapy Symposium. New York, NY. November 2005. Abstract #19.
6 Quintas-Cardana, Kantarjian H, Garcia-Manero G, et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007;109:248-255.
7 Smith B, Kasamon Y, Miller C, et al. K562/GM-CSF Vaccination Reduces Tumor Burden, Including Achieving Molecular Remissions, in Chronic Myeloid Leukemia (CML) in Patients (Pts) with Residual Disease on Imatinib Mesylate (IM). Proceedings from the 42nd annual meeting of the American Society of Clinical Oncology. Atlanta, Ga. June 2006. Abstract # 6509.
8 Pinilla-Ibarz J, Cathcart K, Korontsvit T, et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000;95:1781-1787.
9 Qazilbash MH, Wieder E, Rios R et al. Vaccination with the PRI leukemia-associated antigen can induce complete remission in patients with myeloid leukemia. Blood 2004;104:77a, abstract 259.
10 Bocchia M, Gentili S, Abruzzese E, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. The Lancet 2005;365:657-662.
11 Rojas JM, Knight K, Wang L-H, et al. Clinical BCR-ABL peptide vaccination in chronic myeloid leukaemia: Results of the EPIC study. 2005. Blood 2006;108:623a, abstract 2197.
12 Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Granulocyte-Colony Stimulating Factor (Filgrastim) May Overcome Imatinib-Induced Neutropenia in Patients with Chronic-Phase Chronic Myelogenous Leukemia. Cancer 2004;100:2592-2597.
13 Cortes J, O'Brien S, Quintas A, et al. Erythropoietin is Effective in Improving the Anemia Induced by Imatinib Mesylate Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase. Cancer 2004;100:2396-2402.
14 Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Granulocyte-Colony Stimulating Factor (Filgrastim) May Overcome Imatinib-Induced Neutropenia in Patients with Chronic-Phase Chronic Myelogenous Leukemia. Cancer 2004;100:2592-2597
Accelerated Phase: When chronic myeloid leukemia is difficult to control with Gleevec® (imatinib) or other therapies, the white blood count begins to increase. New symptoms may appear and old symptoms may worsen. The spleen may enlarge and/or new abnormal chromosomes can be detected in the bone marrow cells. Eventually, the leukemia becomes completely resistant to treatment and the bone marrow becomes overburdened with large numbers of immature white blood cells known as "blasts". A diagnosis of accelerated phase requires at least one of the following:
The persistent presence of 10-30% myeloblasts in the bone marrow or peripheral blood.
A major increase of the white blood cell count to over 50,000, platelet counts that are increased or decreased and red blood cell levels that are low despite treatment.
Progressive enlargement of the spleen.
Growth of leukemia outside the bone marrow or spleen.
The presence of any cytogenetic abnormality in addition to a Philadelphia chromosome.
Blastic Phase: Greater than 30% myeloblasts in marrow or blood
Copyright © 2021 CancerConnect. All Rights Reserved.
Early Detection
Laboratory Terminology
NHO News
Accelerated Phase
Acute Myeloid Leukemia Consolidation
Acute Myeloid Leukemia Induction
Acute Myeloid Leukemia Screening/Prevention
Chronic Myeloid Leukemia Screening/Prevention
Chronic Phase
Early Stage Cancer of the Throat
Early-stage Asymptomatic CLL
Extensive Small Cell Lung Cancer
Gastrointestinal Stromal Tumors
General Cancer Information
Limited Small Cell Lung Cancer
Lobular Carcinoma in Situ
Localized Ewing's Sarcoma
Localized Osteosarcoma
Locally Advanced Cancer of the Throat
Metastatic Cancer of the Throat
Metastatic Ewing's Sarcoma
Metastatic Osteosarcoma
Myeloproliferative Neoplasms (MPN)
Post-Remission Treatment
Recurrent Cancer of the Throat
Recurrent Ewing's Sarcoma
Recurrent Non-Small Cell Lung Cancer
Recurrent Osteosarcoma
Recurrent Small Cell Lung Cancer
Refractory ALL
Relapsed Acute Myeloid Leukemia
Relapsed Aggressive NHL
Relapsed Chronic Lymphocytic Leukemia
Relapsed Follicular NHL
Relapsed or Refractory Adult ALL
Remission Induction
Renal Cancer
Screening/Prevention
Soft Tissue Sarcoma Screening and Prevention
Stage 0 Larynx Cancer
Stage I Larynx Cancer
Stage I Non-Small Cell Lung Cancer
Stage I-II Aggressive NHL
Stage I-II Follicular NHL
Stage II Larynx Cancer
Stage II Non-Small Cell Lung Cancer
Stage IIE-IV Aggressive NHL
Stage IIE-IV Follicular NHL
Stage IIIA Non-Small Cell Lung Cancer
Stage IIIB Non-Small Cell Lung Cancer
Stage IV Non-Small Cell Lung Cancer
Symptomatic Advanced CLL
The Role of Radiation Therapy for Ewing's Sarcoma
The Role of Surgery for Ewing's Sarcoma
Treatment and Prevention of Bone Metastases
We are located at 4004 Pioneer Woods Drive off of 70th and Pioneers Blvd.
NHO Pharmacy
Oncology Medical Home
DigniCap
Financial Services & Patient Advocacy
The NHO Difference
Friday | 8am - 3pm
PHARMACY HOURS
Monday - Thursday | 8:30am - 4:30pm
Friday | 8:30am - 2:30pm
For medical advice after hours, call 402.484.4900 and leave a message with our answering service. The on-call physician will return your call.
If you speak another language, require sign language or language-assistance services, these are available free of charge to you. Click here for more information.
Español (Spanish) • Tiếng Việt (Vietnamese) • 繁體中文(Chinese) • العربية (Arabic) • unD (Karen) • Français (French) • Oroomiffa (Oromo) • Tagalog (Tagalog – Filipino) • Deutsch (German) • 한국어 (Korean) • नेपाली (Nepali) • Русский (Russian) • ພາສາລາວ (Lao) • کوردی (Kurdish) • فارسی (Farsi) • 日本語(Japanese)
We are a proud member of:
What it means to be a OneHealth Partner >>
Nebraska's First Quality Oncology Practice Initiative (QOPI®) Certified Cancer Care Provider.
What it means to be QOPI Certified >>
© 2022 Nebraska Hematology Oncology
| Email Confidentiality
Radiation Therapy for Bladder Cancer
Recurrent Bladder Cancer
Stage 0 Bladder Cancer
Stage I Bladder Cancer
Stage II Bladder Cancer
Stage III Bladder Cancer
Stage IV Bladder Cancer
Surgery for Bladder Cancer
Bone Complications and Cancer
Osteosarcoma Overview
Radiation Therapy for Brain Tumors
Surgery for Brain Tumors
Breast Cancer Screening/Prevention
Hormonal Therapy for Breast Cancer
Inflammatory Breast Cancer
Recurrent Breast Cancer
Stage I Breast Cancer
Stage II Breast Cancer
Stage III Breast Cancer
Stage IV Breast Cancer
Surgery for Breast Cancer
Cervical Cancer Screening/Prevention
Precancerous Changes to the Cervix
Radiation Therapy for Cervical Cancer
Recurrent Cervical Cancer
Stage I Cervical Cancer
Stage II Cervical Cancer
Stage III Cervical Cancer
Stage IV Cervical Cancer
Surgery for Cervical Cancer
Colon Cancer Screening/Prevention
Diagnosis and Tests for Colon Cancer
Radiation Therapy for Colon Cancer
Recurrent Colon Cancer
Risk factors for Colon Cancer
Stage I Colon Cancer
Stage II Colon Cancer
Stage III Colon Cancer
Stage IV Colon Cancer
Surgery for Colon Cancer
Symptoms of Colon Cancer
Treatment & Management of Colon Cancer
Radiation Therapy for Esophageal Cancer
Recurrent Esophageal Cancer
Stage 0 Esophageal Cancer
Stage I Esophageal Cancer
Stage II Esophageal Cancer
Stage III Esophageal Cancer
Stage IV Esophageal Cancer
Surgery for Esophageal Cancer
Cause of Gastric Cancer
Diagnosis & Tests for Gastric Cancer
Precision Cancer Medicines for Gastric Cancer
Symptoms & Signs of Gastric Cancer
Treatment & Management of Gastric Cancer
Treatment of Stage 0-I Gastric Cancer
Treatment of Stage IV-Metastatic Gastric Cancer
Treatment of stage II-III Gastric Cancer
Larynx Cancer
Radiation Therapy for Head And Neck Cancers
Throat Cancer
Diagnosis & Tests for Hodgkin Lymphoma
Hodgkin Lymphoma Screening/Prevention
Radiation Therapy for Hodgkin Lymphoma
Relapsed Hodgkin Lymphoma
Stage I/IIA Hodgkin Lymphoma
Stage IIB Hodgkin Lymphoma
Stage III/IVA or B Hodgkin Lymphoma
Symptoms & Signs of Hodgkin Lymphoma
Treatment & Management of HL
Adult Acute Lymphoblastic Leukemia
Childhood Acute Lymphoblastic Leukemia
Liver Cancer Screening/Prevention
Treatment & Management of Liver Cancer
Treatment of Hepatocellular Carcinoma
Lung Cancer Screening & Prevention
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Surgery for Lung Cancer
Diagnosis & Tests for Melanoma
Melanoma Screening/Prevention
Melanoma in Situ (Stage 0)
Symptoms & Signs of Melanoma
Treatment & Management of Melanoma
Treatment of Stage I-II Melanoma
Treatment of Stage III Melanoma
Treatment of Stage IV – Metastatic Melanoma
Radiation Therapy for Malignant Pleural Mesothelioma
Stage I-III Malignant Pleural Mesothelioma
Stage IV/Recurrent Malignant Pleural Mesothelioma
Recurrent Multiple Myeloma
Solitary Plasmacytoma Multiple Myeloma
Stage I Multiple Myeloma
Stages II-III Multiple Myeloma
Supportive Care for Multiple Myeloma
Chemotherapy without SCT for MDS
High-Dose Therapy with Stem Cell Transplant for MDS
Strategies to Improve Treatment of MDS
Supportive Care of MDS: Blood Cell Growth Factors
Targeted Therapy for MDS
Essential Thrombocythemia
Myelofibrosis
Intermediate Grade/Aggressive Grade NHL
Lymphoma Classification
Diagnosis & Tests for Ovarian Cancer
Ovarian Cancer Screening & Prevention
Radiation Therapy for Ovarian Cancer
Recurrent Ovarian Cancer
Stage I-II Ovarian Cancer
Stage II Ovarian Cancer
Stage III Ovarian Cancer
Stage IV Ovarian Cancer
Surgery for Ovarian Cancer
Symptoms & Signs of Ovarian Cancer
Treatment & Management of Ovarian Cancer
Diagnosis & Tests for Pancreatic Cancer
Precision Cancer Medicine for Pancreatic Cancer
Recurrent Pancreatic Cancer
Signs & Symptoms of Pancreatic Cancer
Stage I-II Pancreatic Cancer
Stage III Pancreatic Cancer
Stage IV Pancreatic Cancer
Surgery for Pancreatic Cancer
Treatment & Management of Pancreatic Cancer
Chemotherapy & Targeted Therapy
Hormone Therapy for Prostate Cancer
Radiation Therapy for Prostate Cancer
Stage I Prostate Cancer
Stage II Prostate Cancer
Stage III (C) Prostate Cancer
Stage IV (D) Prostate Cancer
Surgery for Prostate Cancer
Radiation Therapy for Rectal Cancer
Recurrent Rectal Cancer
Stage I Rectal Cancer
Stage II Rectal Cancer
Stage III Rectal Cancer
Stage IV Rectal Cancer
Surgery for Rectal Cancer
Diagnosis & Tests for Renal Cell Cancer
Radiation Therapy for Renal Cancer
Recurrent Renal Cancer
Stage IV-Metastatic Kidney Cancer
Surgery for Renal Cancer
Symptoms & Signs of Renal Cell Cancer
Treatment & Management of Kidney Cancer
Treatment of Stage I – III Kidney Cancer
Ewing's Sarcoma Overview
Kaposi's Sarcoma
Soft Tissue Sarcomas
Overview of Non-Melanoma Skin Cancer
Skin Cancer Screening and Prevention
Treatment for Non-melanoma Skin Cancer
Non-Seminoma: Refractory
Non-Seminoma: Stage I
Non-Seminoma: Stage II
Non-Seminoma: Stage III
Radiation Therapy for Testicular Cancer
Seminoma: Refractory
Seminoma: Stage I
Seminoma: Stage II
Seminoma: Stage III
Diagnosis & Tests for Thyroid Cancer
Signs & Symptoms of Thyroid Cancer
Stage I-II Thyroid Cancer
Stage III Thyroid Cancer
Stage IV Thyroid Cancer
Treatment & Management of Thyroid Cancer
Radiation Therapy for Uterine Cancer
Recurrent Uterine Cancer
Stage I Uterine Cancer
Stage II Uterine Cancer
Stage III Uterine Cancer
Stage IV Uterine Cancer
Surgery for Uterine Cancer
Uterine Cancer Screening/Prevention


At Material Handling Technologies, we specialize in fall protection systems that help prevent injuries while working at an elevated level. Our products are custom designed to meet your business's needs and keep you and your employees safe and working efficiently, no matter how large the structure.
See some of the different types of fall arrest systems we specialize in below. If you're interested in a different type or would like more information about the ones listed, please contact us.
Cable fall arrest systems installed in foundry's and steel mills.
Aluminum track systems for refrigeration areas and cleanrooms.


What reporters get wrong: They oversimplify and mischaracterize the political, social, and cultural nature of rural areas. How to get it right: Editors should try, if possible, to commission stories from local reporters who know their communities. Read more about the issue in this Journalist's Resource tip sheet.


Yunnan Province, the birthplace of tea, is famous for its golden-tipped black teas derived from ancient Assamica variety tea plants. These prizes are among the most intriguing teas you will ever taste - malty, creamy and redolent of truffles. Largely without bite, they reflect the beauty of the complex landscape in which they are cultivated.
For some time now, this has been my favorite tea, and the favorite of my youngest daughter. We do a little bonding over the occasional cuppa with a little shortbread on the side.
Just a tiny bit smoky, this is a rich, nutty cup with beautiful dark orangy brown color. If you don't follow instructions and let it steep too long, it can be rescued with a little whole milk. I rather like it that way on purpose sometimes. This is a smooth, comforting cup of tea.
Thus far, this is my family's favorite black tea. It is very smooth, never styiff, very much like truffles. We have reordered it several times. Our only caution is it does not make the best iced tea.
This tea has a decided smoky flavor that was not mentioned in the official description. Its a nice taste but it should have been mentioned.


يقع في Manly, مانلي بيتشسايد أبارتمنتس إنه المكان الأنسب لاكتشاف سيدني و ما يحيطها. يجذب هذا الفندق ذو 2 نجوم، والذي يبعد 15 km فقط عن وسط المدينة و 25 km عن المطار، الكثير من الزوار سنوياً. بالنسبة لمن يريد الخروج، هذه بعض المعالم السياحية المتوفرة للزوار مانلي اكويرم, دايف سنتر مانلي, مانلي.
استمتع بالخدمات الراقية والضيافة التي لا مثيل لها بهذا الفندق في سيدني. يمكن الاستمتاع بمجموعة من الخدمات على أعلى المستويات في الفندق كمثل خدمة التنظيف يوميًا, تخزين الأمتعة, صف السيارات, خدمة غسيل الملابس, مكان مخصص للتدخين.
تنعكس أجواء مانلي بيتشسايد أبارتمنتس في غرف الضيوف.تلفزيون بشاشة مسطحة, اتصال لاسلكي بشبكة الإنترنت (مجاني), غرف لغير المدخنين, مروحة, تلفزيون هي بعض الميزات الموجود في العديد من الغرف. كما أن مجموعة الخدمات الواسعة الموجودة في الفندق لضمان راحتك تترك لك الكثير من الخيارات لقضاء وقتك أثناء فترة إقامتك. استمتع بخدمات لا يعلى عليها وعنوان ذو اعتبار في مانلي بيتشسايد أبارتمنتس .
تقع جميع غرف النزلاء في الطابق الأول. يقتصر الوصول للغرف داخل مكان الإقامة على الدرج فقط.
مواقف السيارات في الموقع محدودة. ويجب الحجز مسبقًا.
تتوفر مواقف للسيارات في الموقع مقابل رسم إضافي بقيمة 15 دولارًا أستراليًا في الليلة الواحدة أو 40 دولارًا أستراليًا في الأسبوع.
يفتح مكتب الاستقبال من الساعة 02:00 مساءً إلى 05:00 مساءً من الإثنين إلى السبت. يجب على النزلاء الذين سيصلون في وقتٍ آخر غير الأوقات المذكورة أن يتصلوا بالعقار مباشرةً قبيل وصولهم؛ وذلك حتى يمكن إجراء ترتيبات بديلة.
The location is good. That about it. Bathroom door does not shut properly. Unable to use toaster due the extra sensitive fire alarm. I had take cold shower due to the same reason.
Near beach and shops. Lots of steps to reach rooms.
Should have gotten a refund for the last night wasn't happy at all !
The property itself wasn't too bad although we had rooms at the front of the building and the noise from the traffic below was pretty bad. The worse thing about our stay was the lack of parking. Having to move our vehicle every two hours was just ridiculous.
While the place serviced our needs, the room was nothing special. The thing that put me off the most was that the floor had about a 5 degree slop on it which meant that we had to rotate the bed around about 90 degrees so that it didn't feel like we were sleeping on a downhill slop. Room was very clean; bathroom was nothing special but was clean.
Tidy, presentable room. Great staff, very helpful.
Rooms not clean, reception only manned 2pm-5pm.
Thanks for your review. Our reception is manned from 2pm - 5pm that is correct, however we do have a night manager who is on hand outside of those time and always happy to help. We have a great team of cleaners, i'm sorry to hear you were disappointed. We do regularly check the standard and always welcome feedback.
Staircase is a killer. No lift.
This place is nothing like the website when booked. Too many issues to write down here.. long story short. Stay somewhere else.. filthy smelly and honestly this place should be reported to the health department. Somewhat ruined my partner and I little weekend getaway.
Wouldn't recommend i summer as there was no aircon. Showers were very average.
This was a last minute booking for us by someone else, and we would have done better to pay more attention to other reviews before confirming. First things first, if you want to be near the beach at Manly this place is well located as it's only one street back (but see my comment below about the road). Now for the rest: it's apparently managed by the Backpacker Hostel round the corner, and the backpacker mentality is apparent in the way it's managed and fitted out. On arrival you have to leave a $30 deposit for the keys, fair enough, but instead of taking an imprint of your credit card and then cancelling it (like 99% of other places do) they actually deduct the money and then refund it afterwards. If you're from overseas this means you pay two bank transactions, each with fees. When we pointed this out we were told "I don't know the difference [between cancelling and refunding]". Well I'm afraid in this line of work you should know the difference! There are then about 35 steps to get to the apartments (no lift), which can be difficult with heavy/voluminous luggage. The kitchen is decorated with signs telling you you'll have to pay a $2000 fire brigade call out fee if you burn the toast (see what I mean about backpacker mentality?). The room we were in faced out onto the main road, as there is no double glazing or sound insulation of any sort it was very noisy, especially in the morning. The bathroom door was on a noisy sliding runner, impossible to go to the toilet in the middle of the night without waking your partner. Wifi was not free (seriously in this day and age?); it was the only place we stayed in during a month's travels in Australia where we would have had to pay, however at the backpacker hostel round the corner they at least had 30 minutes free (according to the sign plastered on the front of that building). If you're looking for accommodation that's only one step up from a hostel this is for you, otherwise avoid.
Okay so this is not the Hilton, but you would be hard pushed to find better accommodation in Sydney at this price. The staff are great. The bed is comfortable and extra pillows were provided upon request. Nice hot shower. Just a few minutes walk to the shops, beach and ferry. We have stayed here quite a few times and it suits us just fine.
Pictures on Agoda do not reflect the rooms at all and is deceiving. The entry and foyer were very poor and carpet a disgrace. Yes the price is low for the location however the state of the rooms is unacceptable. Room was cockroach infested, bed rusty, wifi so slow it was almost unusable. We were advised by local cals that for the same money you could stay in a great bed and breakfast.


Takuvaine Member of Parliament Mark Brown travelled to Brunei earlier this month to attend a regional telecommunications meeting.
Prime Minister Henry Puna has advised the Head of State to summons Parliament for a sitting to commence on October 8.
Current Leader Wilkie Rasmussen will be remaining at the helm of the Democratic Party until the Party chooses its new chief at a conference roughly scheduled for early next year.
Senior members of the public service were in attendance yesterday for the first day of a workshop that hopes to improve government's ability to implement policy.
Despite having only two elected members, the prospect of One Cook Islands being a necessary partner in the nation's next government is increasingly becoming a reality.
Celebrating the elderly and their ongoing contributions to society will be the focus of International Day of Older Persons this Wednesday.
Prime Minister Henry Puna will be advising the Head of State to summon Parliament early next week, says his chief advisor.
Prime Minister Henry Puna returns this weekend from New York City where he attended a series of meetings, including the high level United Nations Climate Summit.
Right on schedule, the HMNZS Otago arrived in Rarotonga on Friday.


text:
Tesla's Musk sees fully autonomous car ready in 5 years
Submitted by Kpg81 on September 17, 2014
Chief Executive Officer Elon Musk said the technology to make a fully autonomous car will be ready in five or six years, and the result will be a vehicle far less likely to harm occupants and others on the road.
"They will be a factor of 10 safer than a person [at the wheel] in a six-year time frame," Musk said in an interview with The Wall Street Journal. Once the technology is available, it likely would take several more years, however, to work out the regulatory impediments, he said.
Palo Alto, Calif.-based Tesla is working on its own autonomous driving technology for its electric vehicles in addition to talking with auto suppliers. He said he expects more suppliers of autonomous vehicle parts to emerge in coming years.
Musk said "machine vision," or the ability for a computer to quickly recognize objects, is the biggest technological impediment to fully implementing the technology.
Determining what an entire object might be when only a piece of it is visible by camera or radar is a key issue for the technology to determine the correct course of action for the vehicle. "It's kind of scary: what's going to become of us humans," he joked.
http://www.marketwatch.com/story/teslas-musk-sees-fully-autonomous-car-r...
Hmm. I don't want a machine responsible for transporting my family. I am against these self driving cars.
socalsam | September 17, 2014
I really think that sometimes Elon should practice the art of under promise and over deliver. The delays with the Model X. The delays with 6.0. I mean how much was that hyped up and when it finally came out -its a big turd. Nothing special about it.
Quit wasting time on autonomous driving- get the model x out asap without further delays.
logicalthinker | September 17, 2014
I think 6.0 was intended to be much more but they had to cut out a lot.
Did you see the thread over at TMC re: active safety features?
johncrab | September 17, 2014
Elon is a futurist and I admire him for this. There are enough of us concentrating on the immediate now. A car that was aware in a hemispheric bubble would have many advantages. It could know where cars are, how fast they are going, where pedestrians are and then could use sensors to "see" in realtime, providing two stages of data. Collecting the first stage requires infrastructure which isn't here yet. Someone has to hang the dot out in space and say "That's where we need to go".
Red Sage ca us | September 17, 2014
johncrab wrote, "Someone has to hang the dot out in space and say 'That's where we need to go'."
And that's why we credit Elon Musk with having vision, and thus, being a visionary. This is something I understand, as an artist. Before I draw something, no matter the medium, I sit with a blank canvas first. I know what I want to put there, but I must formulate the means by which it will be made to come about. I literally envision the end result, and work backward to the blank sheet of paper, then begin working. It's a process that confuses people who don't work that way.
I was sitting at my desk staring at a blank screen a couple of decades ago at an architectural firm. One of the partners walked by, on his way to get some coffee. He asked what I was doing. I said, "Working." When I was ready, I started using the CAD system to lay out the plans. Naturally, everything was done on time, crisp, clean, ready to go, without delays.
It is rather hard to communicate why such a process can sometimes take a long time. But it is certainly better than going in the wrong direction, and realizing you have to start over again. Once you are done though, the time has passed by so quickly that it is almost like magic. You know you did it, you were there all along, but it almost seemed as if the work did itself. As if it wanted to be created.
It will be ready when it's done.
AmpedRealtor | September 17, 2014
I don't want Mr. Musk to change a single thing about himself. Not one.
It is pretty cool when someone tries to set a trap for Elon by asking a question they don't expect an answer to... and he answers it.
jordanrichard | September 17, 2014
I don't see self driving cars working out, in the wild. There are way, way too many variables. When I am driving, I often pay attention to where the drivers of the other cars are looking. I do this to anticipate a sudden lane change or a similar action that may affect me. A car with 3 hundred radar scopes isn't going to be able to do this. Will an automatous car slam on the brakes when there is a squirrel in the road, when most of us would keep on driving, knowing 9 times out of tem, the squirrel turns around to go back into the woods.
How would these cars react to a an object in the road like the squirrel that doesn't make it....
nick-r | September 17, 2014
Kpg81 | September 17, 2014
This is a concept image of the Tesla self driving car and the AI powered robot that navigates you
jordanrichard: 99 out of 100... There was this one squirrel that committed suicide under a van I was driving...
kpg1981: Well, actually...
Sure, it's Google, but those seats look awfully familiar...
Bubba2000 | September 17, 2014
Tesla should focus in installing simple safety features that are available is plain mid end autos:
- Adaptive cruise control that can work in stop and go traffic in all weather, day or night.
- Anti collision warning and braking, especially with all gizmo distractions in the car, people texting, etc.
- Lane tracking, lane change warning like in Mercedes Benz
- Loud honk and flash brake lights if about to get rear ended
All this tech is being used by MB, Volvo, GM, etc. Supplied by 3rd parties. I can see 2012-13 not having this tech. But no excuse not to have this tech in 2014 cars. Tesla need to quit talking about pie in the sky autonomous driving and do the basics!
Bubba2000: The problem is that those 'simple safety features' don't work very well. Tesla Motors will do... better.
Brian H | September 17, 2014
More supplies for the Road Kill Kafé. Anyone who brakes for squirrels is a menace.
dborn @nsw.au | September 17, 2014
It would be better still if his vision could focus on getting a launch in Australia. It has been promised for late July, Mid August, and now, "not before October".
C'mon Tesla, let this get done, get us our already built cars (completed since mid August), hopefully with prewiring for the new upcoming technology. and then maybe start looking at self driving cars.
For those folks waiting maybe the X and the 3 might jut have a teensy weensy bit more priority than a self driving car!!!
Bubba2000, many of these "safety" features are really complacency features. If you can't stay in your lane, pull over and take a taxi. Didn't see that car in the next lane via the 3 mirrors on the car, pull over and take a taxi.
Here is one thing I don't think people have given any thought to. These "safety features" may help you with your distracted/non attentive driving but at the end of the day, you are still responsible for whatever happens. You can cry all you want that the bell/whistle etc didn't alert you to the car in the next lane, but the judge is going to say, ".....that's nice. Court adjourned, don't forget to pay on your way out"
michael1800 | September 18, 2014
EM's timeline is more than just a touch aggressive, but, like it or not, that's where we're going to be. I personally look forward to the faster transit times and extra sleep on the way to work.
All this talk about driverless cars - Just get me the Model X already.
Seriously man... I bet Model 3 is still some drawing on a boardroom wall at Tesla HQ. How many people bet it won't even release until 2018-2019? Elon is a visionary, but his visions are so far in the future you have to get his timeframe and way of thinking- this is a guy talking about wanting to land people on Mars. What you and I describe as "soon" is in a few years, soon to him in 20-30 years or more.
kpg1981 queried, "How many people bet it won't even release until 2018-2019?"
Let's see... YOU, Mr. Jim Cramer, and a [SUGAR]load of $h0r+s on Wall Street... So, that makes... Pretty much 'everybody'. And well, 'everyone' knows that 'everybody' is ALWAYS right, after all...
Red, think about it really- for the Model 3 to release you need a fully built and operational Gigafactory and everything else that comes with it. If the Model 3 is released to the public before 2018, Id be shocked.
kpg1981: All of this is being discussed in detail in the General forum here. I have already taken on Naysayers in other threads at great length. It really isn't very hard to build cars -- even electric ones. To put it shortly: you will be shocked.
Bighorn | September 18, 2014
Tesla can make ~300,000 batteries a year without gigafactory support, IIRC
Red, look how long it took to put out v6.0 firmware. The Model X was introduced with a fully operating prototype in 2011, almost 4 years ago- and it won't be delivered to customers until 2015. How the Model 3 is going to pop up out of thin air and be delivered in 1/2 the time of the Model X is mind blowing to me. Tesla has a history of delays, rightfully so as they want a perfect product, but assuming the Model 3 will be mass produced in 2 years at this early stage of the game is so optimistic I can't wrap my head around it. But keep speculating, it's fun right..
Captain_Zap | September 18, 2014
@BH
It was 150k confidently but maybe it might be able to stretch to 200k as per Elon in the last quarterly conference call.
kpg1981: Here's the fun thing... History is... history. History is not defined by TRENDS. Trends come and go, ebb and flow. History is only a record of what has happened in the past. History is not a roadmap of what will occur in the future. If you were not a verifiable Bear/$h0r+ you would understand that concept. By the way, your pessimism is also speculation.
Tesla Motors has not been sitting on their hands since 2012. If they were, then there would not have been a 2.0, 3.0, 4.0, or 5.0 upgrade to firmware, let alone a 6.0 as released recently. And if you knew anything at all about software you might realize that the multitude of iterative changes in TeslaOS firmware since January of this year were of features and fixes that were likely originally expected to appear as part of 6.0 anyway. Tesla perhaps could have just held off on doing any changes at all until now. They chose to handle it otherwise, to the benefit of their Customers, and to your dismay.
I presume that by 'in two years' you mean from the launch of Model X? I'll say again, you may prepare yourself to be 'surprised'. That is the eternal state of shock, awe, and wonderment that befalls $h0r+s in TeslaLand. Get used to it, or get over it, but be sure to get out of the way.
That said... Tesla Motors is constantly learning. They learn from the mistakes of the traditional automobile industry. They learn from the pratfalls of others who attempted to blaze a trail toward new technology and were curtailed by trumped up legal hurdles. They learn from interactions with political figures from local, municipal, county, state, and national persuasions. They learn from the biases and fears of suppliers who are tentative about making a hefty commitment of time and resources to a 'newcomer'. They learn to listen to their detractors and constantly assess the level of concern and viability that should be assigned to their perceived woes.
And all that learning allows them to plan for the future, to progress toward a goal, to make their way forward despite all the obstacles in their way, to overcome doubt, fear, and uncertainty, to stand alone on Mt Olympus overlooking the corpses of the defeated that lay all around them, and the dying who lie crying for mercy.
So Red Sage, you are assuming your guesses and speculation will be correct? Well then we both have something in common. Although my assumptions are realistic.
PS, stock is down today on a strong market open- and will likely resume its correction I spoke of as it could not hold over the $263 technical resistance area.
SamO | September 19, 2014
Driverless cars are coming.
Don't like it, don't buy or use one.
California has mandatory rulemaking that requires CHP to allow driverless (autonomous cars) no later than January 1, 2015.
http://cyberlaw.stanford.edu/wiki/index.php/Automated_Driving:_Legislati...
I've posted this before, but driving is the most dangerous activity most humans undertake in their lives. #1 killer of people 1-35 years old and the #1 causes of disability in ALL AGE GROUPS.
http://seattletimes.com/html/living/2010708175_driving05.html
If driving were an activity one did at the amusement park, Disneyland would have been shuttered years ago.
SamO, I get your argument and do understand the stats. But driving happens to be an activity that we all do in our lives, besides eat and sleep. Of course it is going to have a high statistical death and injury rate.
I just don't see how computers driving us around are able to use common sense in certain scenarios. I will be the last person on the road driving a car manually, and if all cars are computers than they can avoid ME and any mistakes I make then right? I will never let a machine drive me around.
@zap
Confirmed the 200,000 figure--what's 100,000 cars amongst friends?
balabanshik | September 19, 2014
I think I know the reason for the Model X delays now. Tesla just wants to get rid of the whole Delivery Specialist wing, and have the cars auto-deliver themselves...
PBEndo | September 19, 2014
If EV's could merely drive themselves to and from charging stations, that would solve a lot of problems. No more worries about moving your car when charging is complete, it moves itself.
@SamO
I agree that the movement toward autonomous vehicles is unstoppable, and in the long run will benefit us all. The transition is what worries me. The current state of "driving aids" just seem to allow drivers to lower their situational awareness. This latest Infiniti commercial scares the crap out of me.
https://www.youtube.com/watch?v=Id8CQ-vsojQ
It ends with the line - "...leaves you free to drive."
It should say, "it leaves you free to be distracted."
Pungoteague_Dave | September 19, 2014
@RS "multitude of iterative changes in TeslaOS firmware since January of this year were of features and fixes that were likely originally expected to appear as part of 6.0 anyway. Tesla perhaps could have just held off on doing any changes at all until now. "
Hate to say it Reds, but there has been exactly one upgraded feature set released between January and 6.0, and many of us still don't have 6.0. What's your definition of multitude?
Fully Autonomous Cars!?!?! I'd be happy with autonomous orange cones guarding the parking spots at the charging locations...and I don't think that will be happening anytime soon.
Until that magical day arrives, Code Orange is our only hope!
Elon advertised for autonomous driving engineers to report directly to him last year. And NASA is running an X-Prize type competition for sample return 'bots: http://www.nasa.gov/press/2014/september/nasas-2015-sample-return-robot-.... Prize a token $1.5 million for Level 2.
"Soon" 'bots will have 'positronic brains'. Isaac was cautionary about some of the interim developments from that, IIRC.
Pungoteague_Dave: I'm sure those various numbers and decimal points are there for some reason. Including the 5.9, 5.10, 5.11, 5.12 and the variations between each, I'm sure that constitutes at least a few more than 'exactly one' thing that has changed since January. In other news... 'Crack: It does a body good!'
riceuguy | September 19, 2014
@Kpg, whether you approve or not, Google's autonomous vehicles have driven 1,000,000+ miles without a single incident hat occurred when the car was driving autonomously. How many of us have that kind of driving record?
Grinnin'.VA | September 20, 2014
@ kpg1981 | September 18, 2014
"... for the Model 3 to release you need a fully built and operational Gigafactory and everything else that comes with it."
Not quite. All they need is about 10% of the capacity of the GF functioning to get started delivering the MX to customers. They could add capacity a bit at a time, reaching full capacity 3 years after the first MX is delivered to a customer.
Go Tesla!
Ron :)
@PBEndo,
+1000 to "driver's aids" being useless. These aren't products, but horrible "hybrid" solutions to distraction.
The best driver is one that doesn't have to have his/her eyes on the road. Cameras, GPS, LIDAR, map images and machine learning will take what should be a very mundane task and thrust it into the far background.
I look forward to the mobility it will provide to aging boomers.
I look forward to the democratization of transportation, instead of only horrible (buses) or expensive (private vehicle ownerships) options.
I'm also glad that Tesla is not putting these half-baked products into any of their cars.
I'll wait for what Elon is calling "Autopilot".
@kpg,
Humans are notoriously poor predictors of probability.
http://www.psychologytoday.com/articles/200712/10-ways-we-get-the-odds-w...
SamO put all to shame with, "I'm also glad that Tesla is not putting these half-baked products into any of their cars. ... I'll wait for what Elon is calling 'Autopilot'."
Precisely on target. Thank you for condensing the whole thread into these two sentences. Superlative effort.

redpajama_set_name: RedPajamaCommonCrawl


The Presidency on Saturday says outcome of the All Progressives Congress, APC, American-style direct presidential primaries on Friday 28th of September 2018, held across the states with President Muhammadu Buhari as the sole aspirant is a major boost to his success at next year's general election.
According to a statement by Senior Presidential Media Aide, Garba Shehu, "In a more direct way, the huge turnout of millions of registered party members at all voting centres proves that the President has an incomparable ability to reach out to people and mobilise votes.
"It is significant that President Buhari has won a major victory, fair and square through direct nationwide primary, a system that seeks to break the mould. The President has shown that you don't have to be a party owner or go through a difficult inner party consensus to emerge as candidate.
"Beyond this being a victory for the party and the President, it is a message to everyone that development and good governance are more important to our people than divide and rule politics.
"The message in the air from this unique achievement by the APC is that all true democratic parties in the country need to start raising their act by copying the leadership of the President.


text:
<LinearLayout xmlns:android="http://schemas.android.com/apk/res/android"
    android:orientation="vertical"
    xmlns:tools="http://schemas.android.com/tools"
    android:layout_width="match_parent"
    android:layout_height="match_parent"
    android:paddingLeft="@dimen/activity_horizontal_margin"
    android:paddingRight="@dimen/activity_horizontal_margin"
    android:paddingTop="@dimen/activity_vertical_margin"
    android:paddingBottom="@dimen/activity_vertical_margin"
    tools:context=".MainActivity$PlaceholderFragment">

    <ScrollView
        android:layout_height="0dp"
        android:layout_width="match_parent"
        android:layout_weight="1">

        <TextView
            android:id="@+id/messages"
            android:text="CHAT"
            android:layout_width="wrap_content"
            android:layout_height="wrap_content" />

    </ScrollView>

    <LinearLayout
        android:layout_height="wrap_content"
        android:layout_width="match_parent"
        android:orientation="horizontal">

        <EditText
            android:id="@+id/message"
            android:layout_height="wrap_content"
            android:layout_width="0dp"
            android:layout_weight="1"
            android:hint="Message"
            android:inputType="textShortMessage|textMultiLine|textCapSentences"/>

        <Button
            android:layout_height="wrap_content"
            android:layout_width="wrap_content"
            android:layout_gravity="bottom"
            android:text="Send"
            android:onClick="sendMessage"/>

    </LinearLayout>

</LinearLayout>

redpajama_set_name: RedPajamaGithub